Mendel D B, Sidwell R W
Gilead Sciences, Inc., Foster City, CA 94404, USA.
Drug Resist Updat. 1998;1(3):184-9. doi: 10.1016/s1368-7646(98)80038-1.
The recent reports from Hong Kong of an avian influenza virus which caused the death of six people has served to remind us of the constant threat of pandemics posed by influenza. Recently, structure-based drug design has resulted in the discovery of a new class of antiviral agents which specifically target the influenza virus neuraminidase. Two neuraminidase inhibitors are currently undergoing clinical evaluation for the prevention and treatment of influenza virus infection in man. Here we review the results of in vitro and in vivo studies relating to the potential development of resistance to this new class of compounds.
香港近期报告了一种导致6人死亡的禽流感病毒，这提醒我们流感引发大流行的威胁始终存在。最近，基于结构的药物设计发现了一类新的抗病毒药物，这类药物专门针对流感病毒神经氨酸酶。目前有两种神经氨酸酶抑制剂正在进行临床试验，以评估其对人类流感病毒感染的预防和治疗效果。在此，我们综述了与这类新化合物潜在耐药性发展相关的体外和体内研究结果。
